313 related articles for article (PubMed ID: 31309328)
1. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
[TBL] [Abstract][Full Text] [Related]
2. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
3. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
4. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
6. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
7. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
[TBL] [Abstract][Full Text] [Related]
13. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
[TBL] [Abstract][Full Text] [Related]
14. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
[TBL] [Abstract][Full Text] [Related]
15. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
Grotenhuis BA; Shapiro J; van Adrichem S; de Vries M; Koek M; Wijnhoven BP; van Lanschot JJ
World J Surg; 2016 Nov; 40(11):2698-2704. PubMed ID: 27272482
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
[TBL] [Abstract][Full Text] [Related]
20. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]